SMS Pharmaceuticals posts Q1FY23 consolidated loss at Rs. 12.76 Cr
The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.
The product will be manufactured at Lupin’s facility in Goa, India.
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m.
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
MeitY will provide technical support for digitalisation of the Ayush Sector under the Ayush Grid project for a period of three years
Urged stakeholders to come up with similar digital platforms and create homegrown best practices where Indian methods and Indian solutions dominate the digital spaces
Subscribe To Our Newsletter & Stay Updated